Stephen Parker

Dr Stephen Parker has over 30 years of corporate finance, directorship, corporate advisory and investment banking experience within the pharmaceutical and biotechnology sectors in the UK, Europe and North America. He is a non-executive chair of AIM-listed oncology therapeutics company Sareum Holdings, and a non-executive director of AIM-listed RNA-therapeutics focussed company, Silence Therapeutics. Dr Parker held senior consulting roles at a number of listed companies, and has investment banking experience at Baring Brothers, SBC Warburg Dillon Read and Apax Partners. He is FCA authorised, an affiliate of the Institute of Chartered Accountants in England & Wales (ICAEW), and a Fellow of the Royal Society of Chemistry and Royal Society of Medicine.
Bio last updated 16 Mar 2019

Article Timeline

Network Graph

Displaying all related organisations and their related contacts. Hover over a node to display a link to the BNiQ page for that person or organisation.

Access to our data for Stephen Parker is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Stephen Parker is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/10/19

1 year TSR5 year TSR
600thMGC Pharmaceuticals-33%37%
717thFamily Zone Cyber Safety-52%
730 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Non-Executive Director
Year started and most recent title


76th↑MGC Pharmaceuticals$10.1m
78th↑Family Zone Cyber Safety$9.2m
197 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer